health
Elevar Therapeutics Announces FDA Approval of Lyrfigtu (Lirafugratinib) as Second-line Cholangiocarcinoma with FGFR2 Fusion or Other Rearrangement Treatment Option
FORT LEE, N.J., Sept. 23, 2026 (GLOBE NEWSWIRE) -- Elevar Therapeutics, Inc., a majority-owned subsidiary of HLB Co., Ltd. and a fully integrated biopharmaceutical company dedicated to elevating treatment experiences and outcomes for cancer patients, today announced the U.S. Food and Drug Administration (FDA) granted approval for LYRFIGTUTM (lirafugratinib) as a treatment option for patients with cholangiocarcinoma (CCA) with FGFR2 fusion or other rearrangement.
ONLY AVAILABLE IN PAID PLANS
Read Full ArticleShare this story
Up next
Related Stories
Amesite Announces New Sales Win Under NurseMagic® Minimum Enterprise Pricing Model
Globenewswire_fr
aTyr Pharma Announces Alignment with FDA on Phase 3 Study of Efzofitimod in Pulmonary Sarcoidosis
Globenewswire_fr
Biodesix Advances Two Complementary Approaches to Molecular Residual Disease (MRD) Monitoring
Globenewswire_fr
Adventure With a Purpose: A Race Against Blindness Unveils Adventure Package Fundraiser Valued at $350,000
Globenewswire_fr
Re: Management of paracetamol (acetaminophen) toxicity
Bmj